Back to Resource Library
WHO Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention
5 August 2022
WHO guidelines, issued in 2022, recommend injectable cabotegravir (CAB) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. These guidelines provide considerations to support managers, policy makers, researchers, health workers, communities, and other stakeholders in the implementation of projects and programs for injectable CAB for PrEP. It also outlines critical research gaps.
Resources referenced in the guideline are available here.